Thus, it is possible that a higher sCTLA‐4 level inhibits the activation of potent antitumor T cells by blocking B7/CD28 interactions, which in turn helps the residual tumor to grow and increases the incidence of local recurrence. This evidence concerns the gene CD80 and neoplasm.